Ingenza logo

Ingenza

Europe, Edinburgh, City of, United Kingdom, Edinburgh

Description

Ingenza is an industrial biotechnology company.

Investor Profile

Ingenza has backed more than 5 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 0 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series Unknown, Seed rounds (top funding stages).
  • Majority of deals are located in United Kingdom.
  • Strong thematic focus on Biotechnology, Health Care, Medical.

Stage Focus

  • Series Unknown (80%)
  • Seed (20%)

Country Focus

  • United Kingdom (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Ingenza frequently co-invest with?

Lancaster Capital
Europe, Glasgow City, United Kingdom, Glasgow
Co-Investments: 2
Kelvin Capital
Europe, Glasgow City, United Kingdom, Glasgow
Co-Investments: 5
CB
Europe, Buckinghamshire, United Kingdom, Beaconsfield
Co-Investments: 1
Scottish Investment Bank
Europe, Glasgow City, United Kingdom, Glasgow
Co-Investments: 1
Scottish Enterprise
Europe, Glasgow City, United Kingdom, Glasgow
Co-Investments: 3

What are some of recent deals done by Ingenza?

ProFactor Pharma

Newhouse, North Lanarkshire, United Kingdom

ProFactor Pharma provides commercialise and supply recombinant blood factors for the treatment of haemophilia.

BiotechnologyHealth CareMedical
Series UnknownSep 30, 2019
Amount Raised: $2,457,911
ProFactor Pharma

Newhouse, North Lanarkshire, United Kingdom

ProFactor Pharma provides commercialise and supply recombinant blood factors for the treatment of haemophilia.

BiotechnologyHealth CareMedical
Series UnknownJun 1, 2016
Amount Raised: $183,052
ProFactor Pharma

Newhouse, North Lanarkshire, United Kingdom

ProFactor Pharma provides commercialise and supply recombinant blood factors for the treatment of haemophilia.

BiotechnologyHealth CareMedical
Series UnknownMar 21, 2015
Amount Raised: $137,572
ProFactor Pharma

Newhouse, North Lanarkshire, United Kingdom

ProFactor Pharma provides commercialise and supply recombinant blood factors for the treatment of haemophilia.

BiotechnologyHealth CareMedical
Series UnknownJul 28, 2014
Amount Raised: $509,455
ProFactor Pharma

Newhouse, North Lanarkshire, United Kingdom

ProFactor Pharma provides commercialise and supply recombinant blood factors for the treatment of haemophilia.

BiotechnologyHealth CareMedical
SeedAug 31, 2013
Amount Raised: $930,036